Latest Restructuring News

Apiam Animal Health has secured court approval for its corporate scheme, paving the way for a fully franked special dividend payment next month.

FirstWave has unveiled a strategic shift towards AI-powered compliance management, backed by strong user growth for its Open-AudIT platform and significant cost savings from restructuring.

The Federal Court of Australia has approved key restructuring schemes for Global Uranium and Enrichment Limited, paving the way for streamlined shareholder arrangements and regulatory exemptions in multiple jurisdictions.

ION Video Ltd has strengthened its board with the return of its original inventor, Finbar O’Hanlon, alongside CEO Anthony Baker, as the company pivots to become foundational infrastructure for Video Superintelligence.

Ariana Resources has extinguished its outstanding US$782,575 loan with RiverFort by issuing over 40 million shares, leaving the company debt-free and well-capitalised with A$11 million in cash.

Nova Minerals plans to redomicile to the United States following the loss of its foreign private issuer status, while acquiring full ownership of its Estelle Gold and Critical Minerals Project and appointing a US-based CFO.

Credit Corp Group Limited reported a steady half-year profit with a 4% revenue rise, driven by strong US collections and record lending volumes, while advancing its UK presence through a strategic acquisition.

Great Divide Mining has completed its acquisition of the remaining Challenger Mines shares, gaining full ownership and setting a revised, sole-funded development plan targeting initial cashflow by the end of Q3 FY26.

Peak Processing Limited has completed a strategic rebrand and organisational restructure, securing new long-term manufacturing agreements and expanding product listings to strengthen its foothold in North America's regulated cannabis beverage markets.

ResMed Inc. reported robust financial results for Q2 FY2026, driven by strong demand in its Sleep and Breathing Health and Residential Care Software segments. The company also navigates ongoing patent litigation while maintaining solid liquidity and shareholder returns.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

A handful of small caps ripped higher, but plenty still slipped even after good news. This week’s biggest moves came from a platform partnership win, a reinstated stock, and a cash settlement that removed a long-running dispute.